vs
Side-by-side financial comparison of Canaan Inc. (CAN) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $20.8M, roughly 1.3× Canaan Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -18.4%, a 12.6% gap on every dollar of revenue.
Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
CAN vs SMTI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.8M | $27.5M |
| Net Profit | $-3.8M | $-1.6M |
| Gross Margin | 99.9% | 93.2% |
| Operating Margin | -15.9% | 23.5% |
| Net Margin | -18.4% | -5.9% |
| Revenue YoY | — | 4.6% |
| Net Profit YoY | — | 5.3% |
| EPS (diluted) | $-0.05 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.8M | $27.5M | ||
| Q3 25 | $13.8M | $26.3M | ||
| Q2 25 | $11.4M | $25.8M | ||
| Q1 25 | — | $23.4M | ||
| Q4 24 | — | $26.3M | ||
| Q3 24 | $10.2M | $21.7M | ||
| Q2 24 | $4.8M | $20.2M | ||
| Q1 24 | — | $18.5M |
| Q4 25 | $-3.8M | $-1.6M | ||
| Q3 25 | $-1.5M | $-30.4M | ||
| Q2 25 | $-11.9M | $-2.0M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-10.4M | $-2.9M | ||
| Q2 24 | $-5.4M | $-3.5M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | 99.9% | 93.2% | ||
| Q3 25 | 99.9% | 92.9% | ||
| Q2 25 | 99.9% | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | 99.9% | 90.8% | ||
| Q2 24 | 99.8% | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | -15.9% | 23.5% | ||
| Q3 25 | -27.0% | 11.2% | ||
| Q2 25 | -45.5% | -0.1% | ||
| Q1 25 | — | -8.9% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | -77.2% | 3.6% | ||
| Q2 24 | -193.9% | -14.3% | ||
| Q1 24 | — | -8.3% |
| Q4 25 | -18.4% | -5.9% | ||
| Q3 25 | -11.0% | -115.5% | ||
| Q2 25 | -104.4% | -7.8% | ||
| Q1 25 | — | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | -102.7% | -13.2% | ||
| Q2 24 | -112.3% | -17.4% | ||
| Q1 24 | — | -9.5% |
| Q4 25 | $-0.05 | $-0.32 | ||
| Q3 25 | $-0.02 | $-3.40 | ||
| Q2 25 | $-0.25 | $-0.23 | ||
| Q1 25 | — | $-0.41 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | $6.2M | $46.0M |
| Stockholders' EquityBook value | $52.4M | $5.9M |
| Total Assets | $92.5M | $72.9M |
| Debt / EquityLower = less leverage | 0.12× | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | $6.2M | $46.0M | ||
| Q3 25 | $6.2M | $45.1M | ||
| Q2 25 | $6.2M | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $52.4M | $5.9M | ||
| Q3 25 | $44.7M | $6.1M | ||
| Q2 25 | $33.8M | $35.4M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $39.4M | ||
| Q3 24 | $43.6M | $39.8M | ||
| Q2 24 | $56.8M | $41.7M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $92.5M | $72.9M | ||
| Q3 25 | $81.7M | $71.1M | ||
| Q2 25 | $78.0M | $98.8M | ||
| Q1 25 | — | $96.4M | ||
| Q4 24 | — | $88.1M | ||
| Q3 24 | $69.3M | $88.5M | ||
| Q2 24 | $73.7M | $73.4M | ||
| Q1 24 | — | $70.9M |
| Q4 25 | 0.12× | 7.74× | ||
| Q3 25 | 0.14× | 7.33× | ||
| Q2 25 | 0.18× | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $3.9M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 14.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $932.0K | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | — | -9.0% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAN
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
